Electrocardiographic Left Ventricular Hypertrophy Regression Induced by an Angiotensin Receptor Blocker-based Regimen in Hypertensive Patients with the Metabolic Syndrome: Data from the SARA Study

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2008 Mar 11

PMID 18326961

Citations 4

Authors

Carlos Escobar

Vivencio Barrios

Alberto Calderon

Sara Barrios

Rocio Echarri

Josefa Navarro-Cid

Elena Ferrer

Raul Fernandez

Affiliations

Soon will be listed here.

Abstract

The authors assessed the effect of an angiotensin receptor blocker (candesartan)-based regimen on electrocardiographic left ventricular hypertrophy (ECG-LVH) in 276 patients with hypertension, including 141 with the metabolic syndrome (MS). Baseline blood pressure (BP) and ECG-LVH parameters did not differ in patients with and without MS. At the study's end, BP had decreased similarly in both groups. At baseline, 26.1% of patients with MS and 24.7% without MS exhibited ECG-LVH by Cornell product (CorP) criteria (P=NS); 26.8% and 17.2%, respectively, by Sokolow-Lyon product (SokP) (P=.01); 11.4%and 11.8% by Cornell voltage (CorV) (P=NS); and 12.4% and 6.5% by Sokolow-Lyon voltage (SokV) (P=.01). At the study's end, in the MS group, prevalence of ECG-LVH was reduced to 19.5% from 26.1% (P=.001), to 8.5% from 11.4% (P=.01), and to 24.4% from 26.8%(P=.03) by CorP, CorV, and SokP, respectively. In patients without MS, only the CorP criterion showed a significant decrease in ECG-LVH prevalence, declining to 20.5% (P=.01). The relative risk reduction of ECG-LVH was higher in patients with MS according to CorV and SokP criteria (P<.01).

Citing Articles

Angiotensin II-Induced Signal Transduction Mechanisms for Cardiac Hypertrophy.

Bhullar S, Dhalla N Cells. 2022; 11(21).

PMID: 36359731 PMC: 9657342. DOI: 10.3390/cells11213336.

High serum uric acid levels may increase mortality and major adverse cardiovascular events in patients with acute myocardial infarction.

Xu Q, Zhang M, Abeysekera I, Wang X Saudi Med J. 2017; 38(6):577-585.

PMID: 28578435 PMC: 5541179. DOI: 10.15537/smj.2017.6.17190.

Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility.

Barrios V, Escobar C Integr Blood Press Control. 2011; 3:11-9.

PMID: 21949617 PMC: 3172067. DOI: 10.2147/ibpc.s6636.

Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study.

Barrios V, Escobar C, Calderon A, Barrios S, Navarro-Cid J, Ferrer E Heart Vessels. 2010; 25(1):51-6.

PMID: 20091399 DOI: 10.1007/s00380-009-1154-1.

References

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

De La Sierra A, Romero R, Bonet J, Perez M, Lopez J, Ravella R . [Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population]. Med Clin (Barc). 2006; 126(11):406-9. DOI: 10.1157/13086123. View

Barrios V, Escobar C, Calderon A, Tomas J, Ruiz S, Moya J . Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst. 2007; 7(4):236-42. DOI: 10.3317/jraas.2006.044. View

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G . 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25(6):1105-87. DOI: 10.1097/HJH.0b013e3281fc975a. View

Okin P, Roman M, Devereux R, Pickering T, Borer J, Kligfield P . Time-voltage QRS area of the 12-lead electrocardiogram: detection of left ventricular hypertrophy. Hypertension. 1998; 31(4):937-42. DOI: 10.1161/01.hyp.31.4.937. View

Barrios V, Escobar C, Calderon A, Llisterri J, Alegria E, Muniz J . Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis. J Cardiometab Syndr. 2007; 2(1):9-15. DOI: 10.1111/j.1559-4564.2007.06313.x. View

Krauser D, Devereux R . Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz. 2006; 31(4):305-16. DOI: 10.1007/s00059-006-2819-5. View

Casale P, Devereux R, Alonso D, Campo E, Kligfield P . Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987; 75(3):565-72. DOI: 10.1161/01.cir.75.3.565. View

Okin P, Devereux R, Jern S, Kjeldsen S, Julius S, Nieminen M . Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004; 292(19):2343-9. DOI: 10.1001/jama.292.19.2343. View

10.

Ferrara L, Cardoni O, Mancini M, Zanchetti A . Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J Hum Hypertens. 2007; 21(10):795-801. DOI: 10.1038/sj.jhh.1002232. View

11.

Okin P, Devereux R, Jern S, Kjeldsen S, Julius S, Dahlof B . Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension. 2000; 36(5):766-73. DOI: 10.1161/01.hyp.36.5.766. View

12.

Zimmet P, Alberti K, Shaw J . Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-7. DOI: 10.1038/414782a. View

13.

Okin P, Devereux R, Jern S, Kjeldsen S, Julius S, Nieminen M . Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003; 108(6):684-90. DOI: 10.1161/01.CIR.0000083724.28630.C3. View

14.

Klingbeil A, Schneider M, Martus P, Messerli F, Schmieder R . A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003; 115(1):41-6. DOI: 10.1016/s0002-9343(03)00158-x. View

15.

Gami A, Witt B, Howard D, Erwin P, Gami L, Somers V . Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49(4):403-14. DOI: 10.1016/j.jacc.2006.09.032. View

16.

Ford E, Giles W, Dietz W . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3):356-9. DOI: 10.1001/jama.287.3.356. View

17.

Okin P, Roman M, Devereux R, Kligfield P . Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995; 25(2):417-23. DOI: 10.1016/0735-1097(94)00371-v. View

18.

Trenkwalder P . Efficacy and tolerability of candesartan cilexetil in special patient groups. Blood Press Suppl. 2000; 1:27-30. View

19.

Barrios V, Calderon A, Escobar C, Barrios S, Navarro-Cid J, Gonzalez-Pedel V . Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study. J Hypertens. 2007; 25(9):1967-73. DOI: 10.1097/HJH.0b013e3282257145. View

20.

AlFakih K, Walters K, Jones T, Ridgway J, Hall A, Sivananthan M . New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI. Hypertension. 2004; 44(2):175-9. DOI: 10.1161/01.HYP.0000135249.66192.30. View